View Future GrowthHLscience 과거 순이익 실적과거 기준 점검 0/6HLscience 의 수입은 연평균 -85.5%의 비율로 감소해 온 반면, Personal Products 산업은 연평균 30.4%의 비율로 증가했습니다. 매출은 연평균 50.2%의 비율로 감소해 왔습니다.핵심 정보-85.48%순이익 성장률-85.73%주당순이익(EPS) 성장률Personal Products 산업 성장률3.77%매출 성장률-50.17%자기자본이익률-14.44%순이익률-71.34%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 20Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024)Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 22Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023)Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 21Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022)Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021)Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue.모든 업데이트 보기Recent updatesReported Earnings • Mar 20Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024)Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.공시 • Mar 07HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea분석 기사 • Nov 05HLscience Co., Ltd. (KOSDAQ:239610) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe HLscience Co., Ltd. ( KOSDAQ:239610 ) share price has fared very poorly over the last month, falling by a...분석 기사 • Nov 05More Unpleasant Surprises Could Be In Store For HLscience Co., Ltd.'s (KOSDAQ:239610) Shares After Tumbling 25%HLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders that were waiting for something to happen have been dealt a blow...Reported Earnings • Mar 22Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023)Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.공시 • Mar 08HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$44.7m).분석 기사 • Nov 13HLscience Co., Ltd.'s (KOSDAQ:239610) 30% Share Price Plunge Could Signal Some RiskHLscience Co., Ltd. ( KOSDAQ:239610 ) shares have retraced a considerable 30% in the last month, reversing a fair...분석 기사 • Sep 24There's Reason For Concern Over HLscience Co., Ltd.'s (KOSDAQ:239610) Massive 26% Price JumpHLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders would be excited to see that the share price has had a great month...New Risk • Sep 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 110% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩87.4b market cap, or US$65.8m).Reported Earnings • Mar 21Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022)Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.New Risk • Jul 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 50% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩103.1b market cap, or US$79.2m).Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021)Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,400, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total loss to shareholders of 51% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Sep 30HLscience Co., Ltd. (KOSDAQ:A239610) announces an Equity Buyback for KRW 3,000 million worth of its shares.HLscience Co., Ltd. (KOSDAQ:A239610) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares according to the contract with Mirae Asset Daewoo Securities. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on October 04, 2023. As of September 29, 2022, the company had 145,575 and 0 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 17x in the Personal Products industry in South Korea. Total loss to shareholders of 65% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Is New 90 Day High Low • Feb 26New 90-day low: ₩40,900The company is down 3.0% from its price of ₩42,238 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 13% over the same period.공시 • Feb 06HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Dec 28New 90-day high: ₩47,700The company is up 1.0% from its price of ₩47,050 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.Upcoming Dividend • Dec 22First Dividend Is ₩400 Per ShareWill be paid on the 21st of April to those who are registered shareholders by the 29th of December. This is the first dividend for HLscience since going public. The average dividend yield among industry peers is 0.6%.Is New 90 Day High Low • Oct 16New 90-day low: ₩44,000The company is down 22% from its price of ₩56,300 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩44,550The company is down 18% from its price of ₩54,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.매출 및 비용 세부 내역HLscience가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A239610 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 2516,706-11,91717,4541,07930 Sep 2518,099-11,32017,8821,05330 Jun 2518,142-10,10816,90998531 Mar 2517,611-8,71915,3111,21631 Dec 2417,664-7,87714,9421,16830 Sep 2419,695-4,12716,3421,35030 Jun 2422,053-3,47517,7861,33131 Mar 2423,837-2,23917,8581,11631 Dec 2325,587-1,37618,4111,21530 Sep 2327,857-1,69620,2161,12330 Jun 2334,979-1,20024,7361,05431 Mar 2344,887-76131,4971,04731 Dec 2252,7581,59234,8451,02530 Sep 2264,6015,08140,86990930 Jun 2275,0337,59845,72789931 Mar 2290,45012,34852,10684731 Dec 21104,37513,53961,21791530 Sep 21115,88815,34367,27890031 Dec 20143,03619,64284,5161,00131 Dec 1523,7053,53313,694306양질의 수익: A239610 은(는) 현재 수익성이 없습니다.이익 마진 증가: A239610는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A239610은 수익성이 없으며 지난 5년 동안 손실이 연평균 85.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A239610의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A239610은 수익성이 없어 지난 해 수익 성장률을 Personal Products 업계(-5.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A239610는 현재 수익성이 없으므로 자본 수익률이 음수(-14.44%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 19:00종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스HLscience Co., Ltd.는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kyung-rae HanDaishin Securities Co. Ltd.null nullDBS Bank LtdSo Min OhEugene Investment & Securities Co Ltd.3명의 분석가 더 보기
Reported Earnings • Mar 20Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024)Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 22Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023)Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 21Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022)Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021)Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue.
Reported Earnings • Mar 20Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024)Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
공시 • Mar 07HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea
분석 기사 • Nov 05HLscience Co., Ltd. (KOSDAQ:239610) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe HLscience Co., Ltd. ( KOSDAQ:239610 ) share price has fared very poorly over the last month, falling by a...
분석 기사 • Nov 05More Unpleasant Surprises Could Be In Store For HLscience Co., Ltd.'s (KOSDAQ:239610) Shares After Tumbling 25%HLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders that were waiting for something to happen have been dealt a blow...
Reported Earnings • Mar 22Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023)Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
공시 • Mar 08HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$44.7m).
분석 기사 • Nov 13HLscience Co., Ltd.'s (KOSDAQ:239610) 30% Share Price Plunge Could Signal Some RiskHLscience Co., Ltd. ( KOSDAQ:239610 ) shares have retraced a considerable 30% in the last month, reversing a fair...
분석 기사 • Sep 24There's Reason For Concern Over HLscience Co., Ltd.'s (KOSDAQ:239610) Massive 26% Price JumpHLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Sep 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 110% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩87.4b market cap, or US$65.8m).
Reported Earnings • Mar 21Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022)Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
New Risk • Jul 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 50% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩103.1b market cap, or US$79.2m).
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021)Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,400, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total loss to shareholders of 51% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Sep 30HLscience Co., Ltd. (KOSDAQ:A239610) announces an Equity Buyback for KRW 3,000 million worth of its shares.HLscience Co., Ltd. (KOSDAQ:A239610) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares according to the contract with Mirae Asset Daewoo Securities. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on October 04, 2023. As of September 29, 2022, the company had 145,575 and 0 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 17x in the Personal Products industry in South Korea. Total loss to shareholders of 65% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Is New 90 Day High Low • Feb 26New 90-day low: ₩40,900The company is down 3.0% from its price of ₩42,238 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 13% over the same period.
공시 • Feb 06HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Dec 28New 90-day high: ₩47,700The company is up 1.0% from its price of ₩47,050 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
Upcoming Dividend • Dec 22First Dividend Is ₩400 Per ShareWill be paid on the 21st of April to those who are registered shareholders by the 29th of December. This is the first dividend for HLscience since going public. The average dividend yield among industry peers is 0.6%.
Is New 90 Day High Low • Oct 16New 90-day low: ₩44,000The company is down 22% from its price of ₩56,300 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩44,550The company is down 18% from its price of ₩54,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.